Lista de obras -

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma

artículo científico publicado en 2016

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

artículo científico publicado en 2017

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

scientific article published on 07 August 2019

Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study

scientific article published on 22 October 2019

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

artículo científico publicado en 2014

Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma

scientific article published on 11 January 2019

Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition

artículo científico publicado en 2019

BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells

artículo científico publicado en 2019

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

article

Classification of current anticancer immunotherapies

artículo científico publicado en 2014

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies

artículo científico publicado en 2016

Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy

artículo científico publicado en 2015

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.

artículo científico publicado en 2018

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

artículo científico publicado en 2014

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

artículo científico publicado en 2012

Comment on the American Society of Clinical Oncology Value Statement

artículo científico publicado en 2016

Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors

scientific article published on 01 June 2019

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

scientific article published on 01 December 2018

Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function ⬇️

artículo científico publicado el 1 de abril de 2011

Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma

artículo científico publicado en 2018

Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.

artículo científico publicado en 2014

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

artículo científico publicado en 2019

From the Guest Editor: Adoptive Cell Therapy: Fulfilling Its Promise

scientific article published on 01 November 2015

Frontiers in pigment cell and melanoma research

artículo científico publicado en 2018

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics

artículo científico publicado en 2019

Immune regulatory antibodies: are they the next advance?

artículo científico publicado en 2010

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

artículo científico publicado en 2018

Immunotherapy in the adjuvant setting for high-risk melanoma

artículo científico publicado en 2018

Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation.

scientific article published on 16 March 2016

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

artículo científico publicado en 2020

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials

artículo científico publicado en 2010

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

artículo científico publicado en 2017

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

artículo científico publicado en 2018

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

artículo científico publicado en 2018

Melanoma Prognosis - Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition

scientific article published on 24 January 2020

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

artículo científico publicado en 2016

Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy

artículo científico publicado en 2020

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.

artículo científico publicado en 2017

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.

artículo científico publicado en 2015

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

artículo científico publicado en 2015

Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy

artículo científico publicado en 2017

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

artículo científico publicado en 2016

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

artículo científico publicado en 2017

PD-1 and PD-L1 antibodies in cancer: current status and future directions

artículo científico publicado en 2017

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

artículo científico publicado en 2019

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.

artículo científico publicado en 2016

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

scientific article published on 18 February 2015

Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application

artículo científico publicado en 2018

Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy

artículo científico publicado en 2019

Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors

artículo científico publicado en 2018

Recent advances in adjuvant therapy for patients with melanoma.

artículo científico publicado en 2018

Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients

scientific article published on 09 October 2019

Reply to F. Liang et al.

artículo científico publicado en 2017

Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes

artículo científico publicado en 2016

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas.

artículo científico publicado en 2016

Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis

artículo científico publicado en 2020

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.

artículo científico publicado en 2014

T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model.

artículo científico publicado en 2017

TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?

artículo científico publicado en 2020

The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response

scientific article published on 01 May 2020

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.

artículo científico publicado en 2017

The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients

artículo científico publicado en 2019

WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression.

artículo científico publicado en 2017

Lista de obras de

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma

Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition

BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Classification of current anticancer immunotherapies

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies

Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Comment on the American Society of Clinical Oncology Value Statement

Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function ⬇️

Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma

Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

From the Guest Editor: Adoptive Cell Therapy: Fulfilling Its Promise

Frontiers in pigment cell and melanoma research

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics

Immune regulatory antibodies: are they the next advance?

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Immunotherapy in the adjuvant setting for high-risk melanoma

Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation.

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Melanoma Prognosis - Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

PD-1 and PD-L1 antibodies in cancer: current status and future directions

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application

Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy

Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors

Recent advances in adjuvant therapy for patients with melanoma.

Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients

Reply to F. Liang et al.

Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas.

Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.

T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model.

TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?

The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.

The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients

WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression.